Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 4
1966 10
1967 12
1968 12
1969 16
1970 16
1971 15
1972 15
1973 11
1974 13
1975 16
1976 11
1977 28
1978 33
1979 33
1980 28
1981 43
1982 55
1983 80
1984 100
1985 99
1986 69
1987 99
1988 105
1989 116
1990 115
1991 85
1992 113
1993 72
1994 100
1995 86
1996 87
1997 84
1998 77
1999 100
2000 118
2001 118
2002 127
2003 119
2004 131
2005 152
2006 165
2007 168
2008 157
2009 198
2010 200
2011 209
2012 239
2013 292
2014 275
2015 286
2016 260
2017 230
2018 283
2019 297
2020 419
2021 626
2022 701
2023 634
2024 269

Text availability

Article attribute

Article type

Publication date

Search Results

7,633 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
Hu J, Chen J, Ou Z, Chen H, Liu Z, Chen M, Zhang R, Yu A, Cao R, Zhang E, Guo X, Peng B, Deng D, Cheng C, Liu J, Li H, Zou Y, Deng R, Qin G, Li W, Wang L, Chen T, Pei X, Gong G, Tang J, Othmane B, Cai Z, Zhang C, Liu Z, Zu X. Hu J, et al. Cell Rep Med. 2022 Nov 15;3(11):100785. doi: 10.1016/j.xcrm.2022.100785. Epub 2022 Oct 19. Cell Rep Med. 2022. PMID: 36265483 Free PMC article.
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N; BC2001 Investigators. Hall E, et al. Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577644 Free article. Clinical Trial.
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak DP. Rosenberg JE, et al. Ann Oncol. 2023 Nov;34(11):1047-1054. doi: 10.1016/j.annonc.2023.08.016. Epub 2023 Sep 9. Ann Oncol. 2023. PMID: 37678672 Clinical Trial.
Immunotherapy in Bladder Cancer.
Konala VM, Adapa S, Aronow WS. Konala VM, et al. Am J Ther. 2022 May-Jun 01;29(3):e334-e337. doi: 10.1097/MJT.0000000000000934. Am J Ther. 2022. PMID: 30839322 Review.
7,633 results